常规临床实践中筛查性乳腺MRI结果:与BI-RADS基准的比较
该回顾性研究评估了2010年7月1日至2013年6月30日连续筛查性乳腺MRI检查在常规实践中的结果,共纳入860次检查(566例患者,平均年龄47岁)。异常判读率为15.6%,癌症检出率为22.1/1000,PPV2为21.6%,PPV3为23.8%,13例浸润性癌中位大小10 mm,61.5%淋巴结阴性。结论认为常规实践中的筛查性乳腺MRI结果达到ACR BI-RADS基准,支持广泛使用这些指标。
要点
- 常规筛查性乳腺MRI的异常判读率15.6%、癌症检出率22.1/1000,达到BI-RADS基准。
- 个人乳腺癌病史占筛查指征的42.4%,其MRI表现至少与其他筛查指征相当。
- 浸润性癌中位大小10 mm,61.5%为淋巴结阴性。
核心结论
- 常规临床实践中,不同高危风险患者的筛查性乳腺MRI表现达到美国放射学会BI-RADS基准,支持广泛使用这些指标。
研究设计与样本
- 经机构审查委员会批准、符合健康保险流通与责任法案的回顾性研究,纳入2010年7月1日至2013年6月30日所有连续筛查性乳腺MRI检查,共860次检查(566例患者,平均年龄47岁),结果由病理和/或至少12个月临床和/或影像随访确定。
诊断标准与关键数值
- 异常判读率134/860(15.6%);癌症检出率19/860(22.1/1000);推荐组织诊断的阳性预测值(PPV2)19/88(21.6%);活检实施的阳性预测值(PPV3)19/80(23.8%);13例浸润性癌中位大小10 mm,8/13(61.5%)淋巴结阴性。
临床应用与阅片要点
- 作者认为常规临床实践中筛查性乳腺MRI的表现达到BI-RADS基准,支持广泛使用这些指标;个人乳腺癌病史占筛查检查的42%,该人群的乳腺MRI表现至少与其他筛查指征相当。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
RATIONALE AND OBJECTIVES: The BI-RADS Atlas 5th Edition includes screening breast magnetic resonance imaging (MRI) outcome benchmarks. However, the metrics are from expert practices and clinical trials of women with hereditary breast cancer predispositions, and it is unknown if they are appropriate for routine practice. We evaluated screening breast MRI audit outcomes in routine practice across a spectrum of elevated risk patients.
MATERIALS AND METHODS: This Institutional Review Board-approved, Health Insurance Portability and Accountability Act-compliant retrospective study included all consecutive screening breast MRI examinations from July 1, 2010 to June 30, 2013. Examination indications were categorized as gene mutation carrier (GMC), personal history (PH) breast cancer, family history (FH) breast cancer, chest radiation, and atypia/lobular carcinoma in situ (LCIS). Outcomes were determined by pathology and/or ≥12 months clinical and/or imaging follow-up. We calculated abnormal interpretation rate (AIR), cancer detection rate (CDR), positive predictive value of recommendation for tissue diagnosis (PPV2) and biopsy performed (PPV3), and median size and percentage of node-negative invasive cancers.
RESULTS: Eight hundred and sixty examinations were performed in 566 patients with a mean age of 47 years. Indications were 367 of 860 (42.7%) FH, 365 of 860 (42.4%) PH, 106 of 860 (12.3%) GMC, 14 of 860 (1.6%) chest radiation, and 8 of 22 (0.9%) atypia/LCIS. The AIR was 134 of 860 (15.6%). Nineteen cancers were identified (13 invasive, 4 DCIS, two lymph nodes), resulting in CDR of 19 of 860 (22.1 per 1000), PPV2 of 19 of 88 (21.6%), and PPV3 of 19 of 80 (23.8%). Of 13 invasive breast cancers, median size was 10 mm, and 8 of 13 were node negative (61.5%).
CONCLUSIONS: Performance outcomes of screening breast MRI in routine clinical practice across a spectrum of elevated risk patients met the American College of Radiology Breast Imaging Reporting and Data System benchmarks, supporting broad application of these metrics. The indication of a personal history of treated breast cancer accounted for a large proportion (42%) of our screening examinations, with breast MRI performance in this population at least comparable to that of other screening indications.
引用
- Strigel RM, Rollenhagen J, Burnside ES, et al. Screening Breast MRI Outcomes in Routine Clinical Practice: Comparison to BI-RADS Benchmarks. Acad Radiol. 2016. PMID: 27986508. doi:10.1016/j.acra.2016.10.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。